Noticias de PFE_US
Noticias del mercado
Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company
Pfizer Inc. stock has advanced in recent weeks amid approval of an updated COVID-19 vaccine, with th
CONSHOHOCKEN, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) agreed Wednesday to pay Pfizer Inc. $27 million for worldwide rights to an early-stage antibody-drug conjugate, taking control of CD228V’s development while …
Pfizer (NYSE:PFE) shares approach multi-year highs on vaccine pipeline momentum, upgraded coronavirus vaccine authorization, Lyme program progress, and raised full-year guidance.
Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...
Pfizer has licensed PF-08046031, an antibody-drug conjugate targeting CD228 that it discontinued earlier this year, to Medicus Pharma in a deal worth…
Pfizer Inc. stock has climbed to a fresh 52-week high while investors weigh the latest quarterly fig
Página 30 de 34